



Nagoya University Graduate School of Medicine
Department of Clinical Oncology and Chemotherapy

65 Tsurumai-cho, Showa-ku
Nagoya 466-8550
Japan

Phone: (+81) 52-744-1903
Fax: (+81) 52-744-1903

Dec 30, 2016

Dear Editor:

We hereby submit the revised manuscript entitled "A feasibility study of modified docetaxel, cisplatin and capecitabine (DCX) for stage IV gastric cancer in Japanese patients" (Number ID:03018053) by Osamu Maeda et al. to be considered for publication as an original article in World Journal of Gastroenterology.

The comments of the reviewers have been helpful in allowing us to revise our manuscript. We have attempted to address the questions according to the following:

1. In Table 1, macroscopic type should be indicated.

As requested, macroscopic type has been indicated in revised Table 1.

2. In the present study, three patients underwent gastrectomy with lymphadenectomy. Did these patients receive adjuvant chemotherapy?

Three patients who underwent gastrectomy received adjuvant chemotherapy. The regimens of adjuvant chemotherapy have been described in the revised manuscript.

3. Case 8 had para-aortic metastatic lymph nodes before chemotherapy using DCX. Were these para-aortic lymph nodes dissected?

In case 8, para-aortic lymph nodes were not dissected, which have been described in the revised manuscript.

4. How about pathological response in primary tumor sites of case 5 and 8?

Pathological response of case 5 and case 8 was grade 2 and grade 1b, respectively. That has been written in the revised manuscript.

We thank you for considering our paper for publication in World Journal of Gastroenterology and look forward to hearing from you.

Sincerely,

Osamu Maeda M.D., Ph.D

Department of Clinical Oncology and Chemotherapy
Nagoya University Hospital
65 Tsurumai-cho, Showa-ku, Nagoya 466-8560, Japan